Morgan Stanley Initiates Myriad Genetics With Underperform
November 10, 2014 at 08:47 AM EST
Analysts at Morgan Stanley initiated coverage on shares of Myriad Genetics (NASDAQ: MYGN) with a Underperform rating. The target ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.